Severely reduced lung function is not closely related to walking ability in people with idiopathic pulmonary fibrosis (IPF), a new study indicates. The findings also point to a need to include patients with severely reduced lung function in IPF clinical trials, researchers said. The study, “Idiopathic…
News
People with idiopathic pulmonary fibrosis (IPF) who have had a collapsed lung, a condition known as pneumothorax, are at risk of recurring collapses, and those needing tube drainage are more likely to have poorer outcomes, a study reported. The study, “Pneumothorax in patients with idiopathic pulmonary fibrosis:…
The Pulmonary Fibrosis Foundation (PFF)Â announced that United Therapeutics will sponsor the PFF Registry. The Registry is a research resource that tracks clinical data, samples, and patient-reported outcomes from people living with pulmonary fibrosis in the U.S. According to the PFF, United Therapeutics’ sponsorship of the Registry…
Fatigue can be a significant burden for people with idiopathic pulmonary fibrosis (IPF), and tends to worsen as the disease progresses or, at best, stay “relatively” stable, a study found. Increasing fatigue was particularly evident among younger patients who were least affected at the study’s start, and among those…
The National Organization for Rare Disorders (NORD) is seeking individuals willing to share real-life experiences with rare diseases to speak at its upcoming virtual Living Rare, Living Stronger NORD Patient and Family Forum. The interactive, patient-focused forum will be held online June 26-27. The deadline to apply for…
The first patient has enrolled in a Phase 3 clinical trial testing whether N-acetyl cysteine (NAC), an antioxidant, can be a targeted treatment for a subset of idiopathic pulmonary fibrosis (IPF) patients with a particular gene variant. The trial, called PRECISIONS (Prospective tReatment EffiCacy in IPF uSIng genOtype…
Endeavor BioMedicines has raised $62 million in series A funding to support the launch of two Phase 2 trials evaluating taladegib (ENV-101), its investigational candidate for the treatment of idiopathic pulmonary fibrosis (IPF), the company announced in a press release. The therapy is designed to target the underlying…
Dosing has begun in a second Phase 3 trial testing FibroGen’s investigational antibody pamrevlumab in treating idiopathic pulmonary fibrosis (IPF). Still recruiting eligible patients at sites in three European countries — Georgia, Italy, and Hungary — and in Lebanon, the ZEPHYRUS-2 study (NCT04419558) is expected to enroll 340 people,…
Suppressing MBD2, a DNA-binding protein, reduced the number of pro-fibrotic macrophages — a type of immune cell involved in pulmonary fibrosis (PF) progression — and lessened lung injury and scarring in a mouse model of PF, a…
During 2020, Pulmonary Fibrosis News held to its mission of providing daily coverage of breakthrough discoveries, promising therapies, clinical trials, and other news related to pulmonary fibrosis (PF). As we look forward to continuing to bring news and relevant information to patients, family members, and caregivers dealing with PF…
